Highly Sensitive Method Detects Malaria Parasites
|
By LabMedica International staff writers Posted on 18 Mar 2015 |

Image: A gametocyte of Plasmodium falciparum in a thin blood smear and also seen are ring-form trophozoites and a red blood cell exhibiting basophilic stippling (Photo courtesy of Dr. Mae Melvin).
A large proportion of asymptomatic malaria infections can only be identified by surveillance with molecular methods, yet these infections also contribute to onward transmission to mosquitoes.
New molecular assays that take advantage of genes with multiple copies in the parasite genome have been developed that can detect malaria parasites in human blood at very low levels and might be helpful in the campaign to eradicate malaria.
An international team of scientists led by those at the Swiss Tropical and Public Health Institute (Basel, Switzerland) compared three methods to detect malaria parasites in 498 samples randomly selected from a malaria survey in Tanzania: light microscopy, the current standard molecular assay, and the new assays. Two quantitative polymerase chain reaction (qPCR) assays were developed for ultra-sensitive detection of Plasmodium falciparum, targeting the high-copy telomere-associated repetitive element 2 (TARE-2, ~250 copies/genome) and the var gene acidic terminal sequence (varATS, 59 copies/genome).
Parasites were detected in 25% of samples by light microscopy, in 50% by the standard assay, and in 58% by the new assays. Compared to the new assays, the current molecular standard assay failed to identify 16% of infections, and at least 40% of those contained parasite gametocytes, the parasite stage that is transmitted when mosquitoes bite an infected person. Standard PCR is widely considered a molecular gold standard of malaria diagnosis complementing light microscopy, the traditional gold standard, yet these results suggest that this notion requires revision.
The new assays detect only the most common malaria parasite, P. falciparum, and while they can use very small blood samples collected in the field, the analysis itself needs to be done in a biomedical laboratory. Nonetheless, because low-density infections without disease symptoms are expected to become increasingly common as countries improve malaria control, ultra-sensitive tools such as these will likely be critical for malaria surveillance and for monitoring the progress of malaria control and elimination programs. The study was published on March 3, 2015, in the journal Public Library of Science Medicine.
Related Links:
Swiss Tropical and Public Health Institute
New molecular assays that take advantage of genes with multiple copies in the parasite genome have been developed that can detect malaria parasites in human blood at very low levels and might be helpful in the campaign to eradicate malaria.
An international team of scientists led by those at the Swiss Tropical and Public Health Institute (Basel, Switzerland) compared three methods to detect malaria parasites in 498 samples randomly selected from a malaria survey in Tanzania: light microscopy, the current standard molecular assay, and the new assays. Two quantitative polymerase chain reaction (qPCR) assays were developed for ultra-sensitive detection of Plasmodium falciparum, targeting the high-copy telomere-associated repetitive element 2 (TARE-2, ~250 copies/genome) and the var gene acidic terminal sequence (varATS, 59 copies/genome).
Parasites were detected in 25% of samples by light microscopy, in 50% by the standard assay, and in 58% by the new assays. Compared to the new assays, the current molecular standard assay failed to identify 16% of infections, and at least 40% of those contained parasite gametocytes, the parasite stage that is transmitted when mosquitoes bite an infected person. Standard PCR is widely considered a molecular gold standard of malaria diagnosis complementing light microscopy, the traditional gold standard, yet these results suggest that this notion requires revision.
The new assays detect only the most common malaria parasite, P. falciparum, and while they can use very small blood samples collected in the field, the analysis itself needs to be done in a biomedical laboratory. Nonetheless, because low-density infections without disease symptoms are expected to become increasingly common as countries improve malaria control, ultra-sensitive tools such as these will likely be critical for malaria surveillance and for monitoring the progress of malaria control and elimination programs. The study was published on March 3, 2015, in the journal Public Library of Science Medicine.
Related Links:
Swiss Tropical and Public Health Institute
Latest Microbiology News
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
- H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
- New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
Channels
Clinical Chemistry
view channel
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read moreMolecular Diagnostics
view channel
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read morePathology
view channel
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read more
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
NanoSomiX, Inc. and Beckman Coulter Diagnostics announced a collaboration to explore the development of next-generation immunoassays for neurodegenerative diseases using extracellular vesicles (EVs).... Read more








